ArticlePhysics and imaging in radiation oncology2026
Improved organs-of-interest dose reduction potential with intensity modulated proton therapy and breath-hold in mediastinal lymphoma.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical implementation of intensity modulated proton therapy in breath-hold for mediastinal lymphoma patients using surface monitoring and nasal high-flow therapy.Physics and imaging in radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: For mediastinal lymphoma patients, comparative data on intensity modulated proton therapy in breath-hold (IMPT-BH) versus other radiation techniques remain limited, particularly regarding dose-volume histogram (DVH) metrics and normal tissue complication probability (NTCP) for late side effects. Materials and Methods: This retrospective in silico planning study included 58 lymphoma patients, treated between 2019 and May 2024, having 4D-CT and BH-CT available. Four plans per patient were made: volumetric arc therapy in free-breathing (VMAT-FB), VMAT-BH, IMPT-FB, and IMPT-BH. An absolute dose difference ≥ 1 Gy was considered clinically relevant, and patients were assigned to the optimal technique. Results: IMPT-BH resulted in the lowest average mean heart dose (MHD) at 5.4 Gy ( Conclusions: IMPT-BH achieved the lowest MHD, MLD, and bilateral MBD compared to IMPT-FB, VMAT-BH, and VMAT-FB in the majority of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.